S-1: Azitra Registers 51.8M Shares for Resale Amidst NYSE Compliance Issues

Azitra, Inc. files an S-1 registration statement for the resale of over 51 million shares by selling stockholders, including those from recent capital raises, while facing NYSE American minimum equity non-compliance.

Summary

• The company is registering up to 51,812,293 shares of Common Stock for resale by Selling Stockholders, including shares from the November 2025 Private Placement and the Alumni Capital ELOC Transaction.
• The shares registered for resale comprise 535,759 November Shares, 4,151,741 November Pre-Funded Warrant Shares, 4,687,500 November Common Stock Purchase Warrant Shares, 187,500 November Placement Agent Warrant Shares, 38,408,903 ELOC Shares, and 3,840,890 ELOC Warrant Shares.
• The company will not receive any proceeds from the resale of shares by the Selling Stockholders.
• However, the company may receive up to approximately $1.57 million from the exercise of November Warrants and November Placement Agent Warrants for cash.
• The company may receive up to an additional $14.0 million from the sale of ELOC Shares (in addition to $6.0 million previously received) and up to approximately $2.5 million upon exercise for cash of currently issued ELOC Warrants and ELOC Warrants that may be issued pursuant to this prospectus.
• On October 1, 2025, the company received notification from NYSE American LLC regarding non-compliance with the minimum stockholders' equity requirement of $4.0 million.
• As of June 30, 2025, and September 30, 2025, the company's stockholders' equity was approximately $2.2 million and $2.3 million, respectively, down from $5.7 million on December 31, 2024.
• The company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.
• The independent registered public accounting firm's report for the year ended December 31, 2024, states substantial doubt about the company's ability to continue as a going concern.
• A reverse stock split of 1-for-6.66 took effect on August 21, 2025.
• The company is an early-stage clinical biopharmaceutical company focused on precision dermatology, with lead product candidates ATR-12 (Netherton syndrome), ATR-04 (EGFRi-associated rash), and ATR-01 (ichthyosis vulgaris).
• ATR-12 Phase 1b clinical trial dosed its first patient in August 2024, with initial safety results reported in the first half of 2025 and topline data expected in Q1 2026.
• ATR-04 Phase 1/2 clinical trial dosed its first patient in Q3 2025, having received Fast Track designation in September 2024.
• ATR-01 is in lead optimization and IND-enabling studies in 2025, with an IND filing planned for 2026.
• The company's Common Stock is listed on the NYSE American under the symbol AZTR, with a last reported sale price of $0.3654 per share on December 9, 2025.

Sentiment

Score: 3

Explanation: While the company has promising clinical programs and proprietary technology in a growing market, the severe financial distress, including NYSE non-compliance, recurring losses, a 'going concern' warning, and an extreme decline in stock price, indicates a highly precarious financial position and significant operational risk. The substantial dilution from ongoing capital raises further exacerbates investor concerns.

Positives

• Advancing three lead product candidates (ATR-12, ATR-04, ATR-01) through clinical development, targeting significant dermatological conditions.
• ATR-12 received Pediatric Rare Disease Designation from the FDA in 2020 and IND clearance for Phase 1b in January 2023.
• ATR-04 received IND clearance in August 2024 and Fast Track designation from the FDA in September 2024.
• Proprietary platform includes a microbial library of approximately 1,500 unique bacterial strains and artificial intelligence/machine learning technology for drug discovery.
• Holds an exclusive, worldwide license from Fred Hutchinson Cancer Center for SyngenicDNA Minicircle Plasmid (SyMPL) technologies for genetic engineering in dermatology.
• Experienced leadership team with over 35 years of combined experience in biotechnology management and healthcare investing, including successful exits at previous companies.
• Identified significant market opportunities for lead candidates: ATR-12 with a potential $250 million global sales opportunity by mid-2030 and ATR-04 with a potential $1 billion global sales opportunity by 2030.
• Received approximately $6.0 million from ELOC sales prior to the prospectus date, with potential for an additional $14.0 million from ELOC Shares and $2.5 million from ELOC Warrants.

Negatives

• Received notification from NYSE American on October 1, 2025, for non-compliance with the minimum stockholders' equity requirement of $4.0 million, with equity at $2.3 million as of September 30, 2025.
• Reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.
• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• Significant potential for dilution to existing stockholders due to the registration of over 51 million shares for resale by Selling Stockholders.
• The market price of Common Stock has experienced extreme volatility, dropping from an IPO price of $999.00 per share in June 2023 to $0.3654 on December 9, 2025.
• The company will not receive proceeds from the resale of shares by Selling Stockholders, only from the exercise of warrants for cash.
• Future capital raises may cause further dilution to existing stockholders or impose significant restrictions if debt securities are issued.
• Management will have broad discretion over the use of proceeds from warrant exercises, which may not be invested successfully or improve operating results.

Risks

• Investors may lose all of their investment due to the high degree of risk associated with the company's securities.
• The company will need additional financing to execute its business plan and fund operations, which may not be available on reasonable terms or at all.
• There is substantial doubt about the company's ability to continue as a going concern due to its accumulated deficit and recurring negative cash flow from operations.
• The actual number of ELOC Shares sold and gross proceeds may be less than the potential $20.0 million, impacting future liquidity.
• Terms of the ELOC Purchase Agreement, such as the 4.99% beneficial ownership limitation for Alumni Capital, may limit the company's ability to fully utilize the arrangement for cash resources.
• The market price of the company's Common Stock is subject to wide fluctuations and volatility, potentially leading to substantial losses for investors.
• The issuance of Common Stock to Selling Stockholders, including upon exercise of warrants, may cause substantial dilution to existing stockholders and a decline in the stock price.
• Failure to meet the continued listing requirements of the NYSE American could result in a delisting of the Common Stock, negatively affecting its price and liquidity.
• Future capital raises may dilute existing ownership and/or have other adverse effects on operations, including liens on assets if debt is issued.
• The company has not paid dividends in the past and has no immediate plans to do so, meaning investors should not expect cash dividends.
• Management's broad discretion over the use of proceeds from warrant exercises may not align with investor expectations or improve operating results.
• The company operates in a very competitive and rapidly changing environment, with new risks emerging over time.
• Reliance on third parties to manufacture product candidates.
• Challenges in maintaining, protecting, and enhancing intellectual property.
• Costs associated with initiating and defending intellectual property infringement and other claims.
• Difficulties in attracting and retaining qualified employees and key personnel.
• The need to comply with evolving legal standards and regulations, particularly concerning requirements for being a public company.

Future Outlook

The company expects to report topline data for its ATR-12 Phase 1b clinical trial in the first quarter of 2026 and plans an IND filing for ATR-01 in 2026. The strategic goal is to build a leading precision dermatology company with a sustainable pipeline, actively developing additional product candidates, evaluating strategic partnerships, and leveraging academic collaborations. The company intends to reinvest all future earnings to cover operating costs and remain competitive, with no plans to pay cash dividends in the foreseeable future.

Management Comments

• "Our goal is to build a leading precision dermatology company with a sustainable pipeline of product candidates."
• "We believe that we have established a unique position in advancing the development of biologics for precision dermatology."
• "We expect that most of our genetically engineered product candidates we develop will be eligible for patent protection."
• "We believe our genetic engineering techniques and technologies have applicability outside of the field of medicine, including cosmetics and in the generation of clean fuels and bioremediation."

Industry Context

The company operates within the rapidly growing dermatology drug market, which exceeded $17 billion in 2021 and is projected to grow at an 8.8% compound annual growth rate through 2030. Azitra positions itself as a pioneer in genetically engineered bacteria for therapeutic use in dermatology, leveraging advancements in genomic sequencing for rare skin diseases. Its focus on precision dermatology with engineered proteins and live biotherapeutic products aligns with broader industry trends towards targeted and innovative therapies for specific conditions.

Comparison to Industry Standards

• The company's licensed SyMPL technology potentially enables the genetic engineering of thousands of microbial species, contrasting with the traditional limitation of recombinant protein engineering to less than 20 species in biotech.
• The management team's specialized expertise was developed at notable companies including Pharmacyclics, Acerta Pharma, Castle Creek Biosciences, VYNE Therapeutics (fka Menlo Therapeutics), Revance Therapeutics, Biogen, Novartis, and Connetics Corp.

Corporate Governance

Legal Proceedings

• None explicitly detailed as ongoing litigation in the filing, though 'developments concerning intellectual property rights, including our involvement in litigation brought by or against us' is noted as a risk factor.

Related Party Transactions

• **Alumni Capital LP**: Entered into the November Purchase Agreement (November 24, 2025) and the ELOC Purchase Agreement (April 24, 2025, amended August 26, 2025) for the issuance and sale of Common Stock and warrants. Alumni Capital LP is a Selling Stockholder.
• **Maxim Group LLC / Maxim Partners LLC**: Maxim Group LLC acted as the exclusive placement agent for the November 2025, January 2025, and February 2025 offerings, receiving cash fees and warrants (e.g., November Placement Agent Warrants, January Placement Agent Warrant). Maxim Partners LLC is a Selling Stockholder.

Stakeholder Impact

• **Shareholders**: Face significant potential for dilution from the resale of over 51 million shares. Risk of substantial losses due to extreme stock price volatility and the potential delisting from NYSE American. Existing shareholders' economic and voting interests will be diluted by the issuance of new shares.
• **Employees**: While not directly mentioned, the company's 'going concern' warning and financial instability could indirectly impact employee morale, retention, and job security.
• **Creditors**: The 'going concern' warning, accumulated deficit, and recurring negative cash flow may raise concerns for creditors regarding the company's ability to meet its financial obligations.
• **Patients/Future Customers**: Continued clinical development of product candidates (ATR-12, ATR-04, ATR-01) offers potential future therapeutic benefits, but the company's financial challenges could impact the pace and success of these programs.

Next Steps

• Report topline data for the ATR-12 Phase 1b clinical trial in the first quarter of 2026.
• File an Investigational New Drug (IND) application for ATR-01 in 2026.
• Continue to evaluate strategic partnerships to accelerate development, provide synergistic combinations, or expand into new disease treatments.
• Selectively in-license technologies or product candidates to broaden the platform.
• Consider out-licensing proprietary technologies for non-medical applications such as cosmetics, clean fuels, and bioremediation.
• Leverage and potentially expand existing academic partnerships with institutions like Carnegie Mellon University and Fred Hutchinson Cancer Center.
• Develop a broad portfolio of product candidates beyond the three current lead candidates.
• The company has submitted a plan to regain compliance with NYSE American listing requirements and is awaiting the NYSE American's determination.
• Selling Stockholders may sell or dispose of the registered shares through various methods, including ordinary brokerage transactions, block trades, or privately negotiated transactions.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by NYSE American non-compliance, recurring losses, negative cash flow, and a 'going concern' warning from its auditors. The stock price has plummeted from $999.00 to $0.3654 since its IPO. While there are promising clinical programs, the immediate and substantial dilution from the registration of over 51 million shares for resale, coupled with the precarious financial position, presents an extremely high risk profile. The company's need for continuous capital raises, which further dilute existing shareholders, and the uncertainty of future financing availability make it a highly speculative investment. A seasoned investor would likely recommend selling to avoid further capital erosion given the significant downside risks and lack of a clear path to financial stability.

Keywords

Biopharmaceutical, Dermatology, Clinical Trials, SEC Filing, S-1, Equity Offering, Warrants, Dilution, NYSE American, Going Concern, Capital Raise, Netherton Syndrome, EGFRi Rash, Ichthyosis Vulgaris, Live Biotherapeutic Products, Genetic Engineering, Staphylococcus epidermidis, Orphan Disease, Fast Track Designation, FDA, Alumni Capital, Maxim Group